Analyst Ratings For Charles River Laboratories Intl. (NYSE:CRL)
Today, Morgan Stanley raised its price target on Charles River Laboratories Intl. (NYSE:CRL) to $102.00 per share.
Some recent analyst ratings include
- 2/16/2018-Barclays Reiterated Rating of Hold.
- 2/15/2018-Credit Suisse Group Reiterated Rating of Hold.
- 2/14/2018-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
Recent Insider Trading Activity For Charles River Laboratories Intl. (NYSE:CRL)
Charles River Laboratories Intl. (NYSE:CRL) has insider ownership of 2.20% and institutional ownership of 99.90%.
- On 3/9/2018 George M Milne Jr, Director, sold 7,740 with an average share price of $115.00 per share and the total transaction amounting to $890,100.00.
- On 3/6/2018 Birgit Girshick, Insider, sold 9,893 with an average share price of $109.10 per share and the total transaction amounting to $1,079,326.30.
- On 3/6/2018 James C Foster, CEO, sold 24,008 with an average share price of $110.00 per share and the total transaction amounting to $2,640,880.00.
- On 2/28/2018 David Ross Smith, CFO, sold 100 with an average share price of $108.43 per share and the total transaction amounting to $10,843.00.
- On 2/28/2018 James C Foster, CEO, sold 3,372 with an average share price of $107.39 per share and the total transaction amounting to $362,119.08.
- On 2/26/2018 David Ross Smith, Insider, sold 3,868 with an average share price of $107.35 per share and the total transaction amounting to $415,229.80.
- On 2/26/2018 James C Foster, CEO, sold 4,800 with an average share price of $106.69 per share and the total transaction amounting to $512,112.00.
Recent Trading Activity for Charles River Laboratories Intl. (NYSE:CRL)
Shares of Charles River Laboratories Intl. closed the previous trading session at with shares trading hands.